NRx Pharmaceuticals, Inc.
NRXP
$2.24
-$0.0539-2.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.76% | -43.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.25% | -57.13% | |||
| Operating Income | -20.25% | 57.13% | |||
| Income Before Tax | -459.33% | 79.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -459.33% | 79.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -459.33% | 79.45% | |||
| EBIT | -20.25% | 57.13% | |||
| EBITDA | -20.30% | 57.16% | |||
| EPS Basic | -401.01% | 80.30% | |||
| Normalized Basic EPS | -98.88% | 63.75% | |||
| EPS Diluted | -401.01% | 80.30% | |||
| Normalized Diluted EPS | -98.88% | 63.75% | |||
| Average Basic Shares Outstanding | 11.64% | 4.34% | |||
| Average Diluted Shares Outstanding | 11.64% | 4.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||